• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medication isn't effective. Personalized treatment may be the solution.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into personalised micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that are able to change mood over time.

Predictors of Mood

Depression is one of the most prevalent causes of mental illness.1 However, only about half of those suffering from the condition receive treatment1. To improve outcomes, healthcare professionals must be able identify and treat patients who are most likely to respond to specific treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from certain treatments. They are using sensors for mobile phones as well as a voice assistant that incorporates artificial intelligence, and other digital tools. Two grants worth more than $10 million will be used to determine the biological and behavioral factors that predict response.

To date, the majority of research on factors that predict depression treatment effectiveness (marvelvsdc.faith wrote) has been focused on clinical and sociodemographic characteristics. These include demographics like gender, age and education as well as clinical characteristics such as symptom severity, comorbidities and biological markers.

While many of these factors can be predicted from the information available in medical records, few studies have utilized longitudinal data to determine the factors that influence mood in people. Many studies do not consider the fact that moods can vary significantly between individuals. Therefore, it is essential to develop methods that allow for the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behaviour and emotions that are unique to each individual.

In addition to these modalities, the team created a machine learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated scale for assessing severity of symptom. The correlation was not strong, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1 but is often underdiagnosed and undertreated2. In addition an absence of effective treatments and stigma associated with depressive disorders stop many from seeking treatment.

To assist in individualized treatment, it is important to identify the factors that predict symptoms. However, the methods used to predict symptoms rely on clinical interview, which is unreliable and only detects a tiny number of symptoms associated with depression.2

Machine learning can be used to integrate continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of symptom severity could improve the accuracy of diagnosis and natural treatment for anxiety and depression efficacy for depression treatment plan cbt. Digital phenotypes can be used to provide a wide range of distinct actions and behaviors that are difficult to record through interviews and permit continuous and high-resolution measurements.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online assistance or non medical treatment for depression care based on the severity of their depression. Those with a score on the CAT-DI scale of 35 or 65 were given online support via the help of a coach. Those with a score 75 patients were referred to psychotherapy in-person.

Participants were asked a series questions at the beginning of the study about their demographics and psychosocial characteristics. These included age, sex, education, work, and financial situation; whether they were divorced, married or single; the frequency of suicidal ideas, intent, or attempts; and the frequency with that they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted every other week for the participants who received online support and once a week for those receiving in-person treatment.

Predictors of the Reaction to Treatment

The development of a personalized depression treatment is currently a research priority and a lot of studies are aimed to identify predictors that enable clinicians to determine the most effective medication for each patient. In particular, pharmacogenetics identifies genetic variations that affect how the body's metabolism reacts to antidepressants. This allows doctors select medications that are likely to be the most effective for each patient, reducing the time and effort needed for trials and errors, while eliminating any adverse consequences.

Another promising approach is to build predictive models that incorporate the clinical data with neural imaging data. These models can be used to determine which variables are most predictive of a specific outcome, like whether a medication will improve mood or symptoms. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have shown to be useful in the prediction of treatment outcomes like the response to antidepressants. These approaches are becoming more popular in psychiatry and will likely become the norm in the future treatment.

In addition to the ML-based prediction models, research into the mechanisms behind depression continues. Recent research suggests that the disorder is linked with dysfunctions in specific neural circuits. This suggests that the treatment refractory depression for depression will be individualized focused on therapies that target these circuits to restore normal function.

One method of doing this is to use internet-based interventions which can offer an individualized and tailored experience for patients. For example, one study found that a program on the internet was more effective than standard treatment in alleviating symptoms and ensuring a better quality of life for people with MDD. A controlled, randomized study of a personalized treatment for depression found that a significant number of patients saw improvement over time as well as fewer side negative effects.

Predictors of Side Effects

In the treatment of depression one of the most difficult aspects is predicting and determining which antidepressant medications will have very little or no adverse effects. Many patients are prescribed a variety medications before settling on a treatment that is both effective and well-tolerated. Pharmacogenetics offers a fascinating new method for an efficient and specific approach to choosing antidepressant medications.

There are many variables that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of the patient such as gender or ethnicity, and the presence of comorbidities. However it is difficult to determine the most reliable and valid factors that can predict the effectiveness of a particular treatment is likely to require controlled, randomized trials with significantly larger numbers of participants than those normally enrolled in clinical trials. This is because the identifying of moderators or interaction effects can be a lot more difficult in trials that consider a single episode of treatment per participant instead of multiple sessions of treatment over a period of time.

Additionally, the estimation of a patient's response to a specific medication is likely to require information on symptoms and comorbidities and the patient's prior subjective experience of its tolerability and effectiveness. Currently, only some easily assessable sociodemographic and clinical variables appear to be reliably associated with the severity of MDD like gender, age race/ethnicity, SES, BMI and the presence of alexithymia and the severity of depressive symptoms.

Many issues remain to be resolved when it comes to the use of pharmacogenetics to treat depression. First, it is essential to have a clear understanding and definition of the genetic mechanisms that underlie depression, and a clear definition of an accurate indicator of the response to treatment. Additionally, ethical issues, such as privacy and the responsible use of personal genetic information must be carefully considered. In the long-term pharmacogenetics can offer a chance to lessen the stigma associated with mental health care and improve the treatment outcomes for patients with depression. However, as with any approach to psychiatry careful consideration and implementation is required. For now, the best option is to provide patients with an array of effective medications for agitated depression treatment and encourage them to speak freely with their doctors about their experiences and concerns.